Navigation Links
AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences
Date:2/21/2012

REDWOOD CITY, Calif., Feb. 21, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences, one in New York City, NY and one in Boston, MA, over the coming weeks as follows:

Citi 2012 Global Health Care Conference
Date:  Tuesday, February 28th at 10:30 AM EST
Location:  Waldorf Astoria Hotel in New York, NY
Webcast link:  http://www.veracast.com/webcasts/citigroup/healthcare2012/07206633.cfm

Cowen and Company 32nd Annual Health Care Conference
Date:  Tuesday, March 6th at 9:20 AM EST
Location:  The Boston Marriott Copley Place in Boston, MA
Webcast link:  http://wsw.com/webcast/cowen6/acrx/

Both presentations will be webcast live and can be accessed through the links above.  For those not available to listen to the live broadcast, the presentations will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group ... in Brazil , Russia ... China (BRIC) will see robust expansion ... increasingly favored over surgical procedures. Although revenues will be ... reimbursement challenges, prolonged device approval times and demand for ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... Ky. , Sept. 30, 2014 A ... tomography (OCT), offered a new look at the composition ... alter how physicians understand and treat the disease, a ... conducted at Baptist Health Lexington between September 2010 and ... of the Journal of the American College of ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... UCB) and U.S. based partner Immunomedics Inc. (Nasdaq: ... IIb study, EMBLEM™, showed that certain doses of epratuzumab ... in disease activity in adult patients with moderate to ... designed to evaluate the efficacy and safety of epratuzumab ...
... innovator of Packaging Execution Systems (PES) for the pharmaceutical ... engineering, automation and manufacturing optimization services company, today announced ... Service Provider (SSP). VCG will now sell, install and ... United States. The SSP program is ...
Cached Medicine Technology:Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 2Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 3Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 4Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 5Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 6Epratuzumab Phase IIb Data Presented at ACR Show Pipeline Drug had Positive Effect in Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus 7Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 2Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements 3
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new patient ... higher rates than other primary care practices (non-FQHCs), ... to results of a new 10-state University of ... Care . , Using data from a previous ... the investigators found that FQHCs community health ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Fat Burning ... specialist and best-selling author Mike Geary that is helping people ... their body into a fat-burning machine in less than 24 ... investigative review. , “In our culture that is becoming ... hard to decipher what is really fact and fiction when ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3
... Hammer toes, curly toes, crossover toes and bunions are not only ... a new report warns. According to a review published in ... of Orthopaedic Surgeons , deformities of the lesser toes, which includes ... as early as possible by an orthopaedic surgeon to avoid other ...
... of men undergoing surgery for prostate cancer expect better recovery ... attain one year after the operation, a University of Michigan ... to surgery, a small proportion of men had expected to ... the surgery than they had before it the exact ...
... a recent issue of Cancer Research, Daniel J. Powell, ... Laboratory Medicine and Obstetrics and Gynecology at the Perelman ... for the first time that engineered human T cells ... Ovarian cancer is the most lethal reproductive cancer ...
... In an innovative collaboration designed to speed the process ... California, San Diego Health Sciences announced today that UC ... life science research institutions across the country as part ... collaborative partnerships formed through the Centers for Therapeutic Innovation ...
... -- Smokers who light up right after they wake up in ... neck cancers than those who wait longer before having their first ... was released online Aug. 8 in advance of publication in an ... smokers have higher levels of nicotine and possibly other tobacco toxins ...
... Alexandria, VA Dale Browne, MD, of Winston Salem, ... and Neck Surgery (AAO-HNS) Distinguished Service Award at the ... OTO EXPO, in San Francisco, CA, September 11-14, 2011. ... professionals in recognition of extensive meritorious service through the ...
Cached Medicine News:Health News:Toe Deformities Should Be Treated Early: Experts 2Health News:Men have overly optimistic expectations about recovery from prostate cancer surgery, U-M study finds 2Health News:Penn study finds more effective approach against 'Achilles' heel' of ovarian cancer 2Health News:UCSD Health Sciences partners with Pfizer to speed drug delivery 2Health News:UCSD Health Sciences partners with Pfizer to speed drug delivery 3Health News: Early Morning Smoking Riskier For Cancer 2
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: